TD Cowen Downgrades Sage Therapeutics to Hold, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has downgraded Sage Therapeutics from Buy to Hold and lowered the price target from $16 to $10.
July 30, 2024 | 9:55 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen has downgraded Sage Therapeutics from Buy to Hold and lowered the price target from $16 to $10.
The downgrade from Buy to Hold and the significant reduction in the price target from $16 to $10 by TD Cowen is likely to negatively impact investor sentiment and the stock price of Sage Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100